{"ticker": {"uuid": "60b0f79a-4950-442a-962a-d91e866b4d44", "symbol": "1652", "name": "Fusen Pharmaceutical Company Limited", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Fusen Pharmaceutical Wins China Approval for New Doxazosin Extended-Release Tablets", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTWtfMzI2NmhOcXhubDdpeFJodUNpNlNtWDNHTzJTQW40Zm1tMmtGOTE0Y1hIY1daVUtFNHpXUUxocTYzQ1Fxb3A3MmNhcGUyQ3pJQmlFZ0dQT2IxRGpESGVURkc5TVhMc21lTV96RmljVzZzV3UtcEJIRm4wZHFWb0Y4SWFHRjBtaE9tQ2V1V0o0b056RzZfZEE5SmRWTjBmV0NPTDQ3eDNMVy04QW9aenRmZFN4VEJ6aTNrdzdBNEtHSjRQd2RKTlNBWU41NTM3?oc=5", "source_name": "TipRanks", "published_at": "2026-07-10T12:41:34+00:00", "published_display": "10 Jul 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fusen Pharmaceutical Shareholders Approve RMB300 Million Capital Injection into Henan Subsidiary", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNX1lMS3E0NDZTcFpKc1RoYmF0QWdGNEQ5SENncFdkeV9XNE51dkROd3NaMHVaX0JVSUF3S2stdE81b0VjSmhWZ3NiUm5yU0xXNVRoRGFSY3Z0dkc0OGN3ZzFwMWk3ZFhyRGkwTVExbFNKN1daa0lxU0FSZDBDOG1JSWJkY2hIZ2g0TTduLUJaaUlCeFNYdVZjckdIS3VENkVrWXhGWm9QTXhQd05HakxCeTZjVS0xREd2bi1Sc2RsZWtZWXpNVUhFNlNkNUt4YTAzTGdKTmY0STFKTFBhSklCeHRR?oc=5", "source_name": "TipRanks", "published_at": "2026-07-09T09:25:52+00:00", "published_display": "09 Jul 2026 09:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Fusen Pharmaceutical Co., Ltd. \u2013 HKEX:1652", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPOHZBS3MwWURBQnZqMnIwQmtmR29XczdsQlV5Q2hPengzcnpDd0ZERVFwYkRBblFyNzVlbmtUcl9DcGlVdWxZYURfbV9EWUpkQ2luX1BucUQ2SjNNRmtkQlF1MzkydXpvazRzTEpSV1IzMDlWbk56SThnMmNEY2NJd3BYQnp3UU02aThjdkQ2S3NfM3V0WFhrc0JwZw?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T16:45:46+00:00", "published_display": "26 Jun 2026 16:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exchange\u2019s Disciplinary Action against Fusen Pharmaceutical Company Limited (Stock Code: 1652) and Five Current Directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQWGFHZUN5VVc5MXg4VWFMX1NZenFOWXdjaDJjTjVsU1ltZXhRVkdVU0I5aVhyVm9iZ3V2eHhYd25RM0txalZDNVVja3Z6bWs3Y0JOZWRuV1A5UkJib3VpOHVlQVFfS3hHajNqNGtZcWduajJjZkthWWtnT1A1NUxoNG9Xc3QwZ2M?oc=5", "source_name": "hkex.com.hk", "published_at": "2023-01-04T08:00:00+00:00", "published_display": "04 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Fusen Pharmaceutical Wins China Approval for New Doxazosin Extended-Release Tablets", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTWtfMzI2NmhOcXhubDdpeFJodUNpNlNtWDNHTzJTQW40Zm1tMmtGOTE0Y1hIY1daVUtFNHpXUUxocTYzQ1Fxb3A3MmNhcGUyQ3pJQmlFZ0dQT2IxRGpESGVURkc5TVhMc21lTV96RmljVzZzV3UtcEJIRm4wZHFWb0Y4SWFHRjBtaE9tQ2V1V0o0b056RzZfZEE5SmRWTjBmV0NPTDQ3eDNMVy04QW9aenRmZFN4VEJ6aTNrdzdBNEtHSjRQd2RKTlNBWU41NTM3?oc=5", "source_name": "TipRanks", "published_at": "2026-07-10T12:41:34+00:00", "published_display": "10 Jul 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fusen Pharmaceutical Shareholders Approve RMB300 Million Capital Injection into Henan Subsidiary", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNX1lMS3E0NDZTcFpKc1RoYmF0QWdGNEQ5SENncFdkeV9XNE51dkROd3NaMHVaX0JVSUF3S2stdE81b0VjSmhWZ3NiUm5yU0xXNVRoRGFSY3Z0dkc0OGN3ZzFwMWk3ZFhyRGkwTVExbFNKN1daa0lxU0FSZDBDOG1JSWJkY2hIZ2g0TTduLUJaaUlCeFNYdVZjckdIS3VENkVrWXhGWm9QTXhQd05HakxCeTZjVS0xREd2bi1Sc2RsZWtZWXpNVUhFNlNkNUt4YTAzTGdKTmY0STFKTFBhSklCeHRR?oc=5", "source_name": "TipRanks", "published_at": "2026-07-09T09:25:52+00:00", "published_display": "09 Jul 2026 09:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Fusen Pharmaceutical Co., Ltd. \u2013 HKEX:1652", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPOHZBS3MwWURBQnZqMnIwQmtmR29XczdsQlV5Q2hPengzcnpDd0ZERVFwYkRBblFyNzVlbmtUcl9DcGlVdWxZYURfbV9EWUpkQ2luX1BucUQ2SjNNRmtkQlF1MzkydXpvazRzTEpSV1IzMDlWbk56SThnMmNEY2NJd3BYQnp3UU02aThjdkQ2S3NfM3V0WFhrc0JwZw?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T16:45:46+00:00", "published_display": "26 Jun 2026 16:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exchange\u2019s Disciplinary Action against Fusen Pharmaceutical Company Limited (Stock Code: 1652) and Five Current Directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQWGFHZUN5VVc5MXg4VWFMX1NZenFOWXdjaDJjTjVsU1ltZXhRVkdVU0I5aVhyVm9iZ3V2eHhYd25RM0txalZDNVVja3Z6bWs3Y0JOZWRuV1A5UkJib3VpOHVlQVFfS3hHajNqNGtZcWduajJjZkthWWtnT1A1NUxoNG9Xc3QwZ2M?oc=5", "source_name": "hkex.com.hk", "published_at": "2023-01-04T08:00:00+00:00", "published_display": "04 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 62, "total_relevant": 4, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 4, "score": 50, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 71, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 1.02, "latest_week": "2026-07-10", "one_week_move": 1.0, "four_week_move": -1.9, "twelve_week_move": -16.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.051193, "market_dynamics_buy_signal": false, "relative_strength": 27.831611, "fair_value_gap": 10.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 36.1089, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.0% over one week, -1.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TipRanks", "count": 2}, {"label": "TradingView", "count": 1}, {"label": "hkex.com.hk", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "71/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.0% over one week, -1.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Fusen Pharmaceutical Wins China Approval for New Doxazosin Extended-Release Tablets"}], "updated_at": "2026-07-18T00:59:33.927781+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}